NCT02092922已完成2 期
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 154
- 试验地点
- 60
- 主要终点
- In patients with low Baseline alpha 1-acid glycoprotein (AAG), assess the efficacy of the study drug in terms of objective response rate.
研究概览
简要总结
The AfFIRM Study is a Phase 2 study during which patients with advanced multiple myeloma will receive single-agent investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of filanesib in treating myeloma. Approximately 160 patients from North America and Europe will be enrolled in this study.
Eligible patients will have received at least two prior lines of therapy; have received prior bortezomib and lenalidomide; and have disease refractory to carfilzomib and/or pomalidomide.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with confirmed multiple myeloma whose treatment history must include all of the following:
- •Received at least 2 prior lines of therapy (induction therapy and stem cell transplant ± maintenance are to be considered a single line of therapy).
- •Received at least 2 cycles of a bortezomib-containing regimen and 2 cycles of a lenalidomide-containing regimen, unless intolerant to these agents (defined as requiring discontinuation due to toxicity).
- •Disease refractory to a carfilzomib-containing regimen and/or a pomalidomide containing regimen. Refractory is defined as either failure to achieve a minimal response (MR) or better while on therapy, or development of progressive disease (PD) while on therapy or within 60 days from last dose of therapy.
- •Measurable multiple myeloma disease, defined as meeting at least one of the following criteria within 14 days prior to first dose of study drug:
- •A monoclonal Ig (M-protein) concentration on serum protein electrophoresis (SPEP) of ≥ 1.0 g/dL.
- •Measurable urinary light chain secretion by quantitative analysis using urine protein electrophoresis (UPEP) of ≥ 200 mg/24 hours.
- •Involved serum free light chain (FLC) level ≥ 10 mg/dL, provided the serum FLC ratio is abnormal.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 within 14 days prior to first dose of study drug.
- •Adequate hematology, hepatic and renal function laboratory values within 14 days prior to first dose of study drug.
- •Additional criteria exist.
排除标准
- •Prior treatment with filanesib (ARRY-520) or any other KSP inhibitor.
- •Past or current plasma cell leukemia.
- •Primary amyloidosis (amyloidosis associated with multiple myeloma is allowed).
- •POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes).
- •Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to first dose of study drug.
- •Concomitant malignancies or previous malignancies (other than multiple myeloma) with less than a 2-year disease-free interval at the time of first dose of study drug. Patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or Stage 1 prostate cancer are eligible irrespective of the time of diagnosis.
- •Use of an investigational agent that is not expected to be cleared by the time of first dose of study drug or that has been demonstrated to have prolonged side effects. Patients must have recovered from all side effects to a Grade 0 or 1 (except alopecia and neuropathy).
- •Any severe concurrent disease or condition (including severe graft-versus-host disease, requirement for dialysis, symptomatic congestive heart failure [New York Heart Association Class III or IV], unstable angina pectoris, cardiac arrhythmia) which, in the judgment of the Investigator, would make the patient inappropriate for study participation.
- •Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or hepatitis C.
- •Acute active infection requiring treatment.
- •Additional criteria exist.
研究组 & 干预措施
Filanesib
Experimental
干预措施: Filanesib, KSP (Eg5) inhibitor; intravenous (Drug)
Filanesib
Experimental
干预措施: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous (Drug)
结局指标
主要结局
In patients with low Baseline alpha 1-acid glycoprotein (AAG), assess the efficacy of the study drug in terms of objective response rate.
时间窗: up to 2 years
次要结局
- In all patients, assess the efficacy of the study drug in terms of duration of response.(up to 2 years)
- In all patients, assess the efficacy of the study drug in terms of progression-free survival.(up to 2 years)
- In all patients, assess the efficacy of study drug in terms of overall survival.(up to 2 years)
- In all patients, assess the safety of the study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.(up to 2 years)
- In a subset of all patients, characterize the pharmacokinetics (PK) of the study drug in terms of plasma concentration-time profiles.(6 months)
- In patients with high Baseline AAG, assess the efficacy of the study drug in terms of objective response rate.(up to 2 years)
- In a subset of all patients, assess the correlation between study drug exposure and changes in corrected QT interval (QTc) in terms of changes in QTc versus time-matched study drug plasma concentrations.(6 months)
研究者
研究点 (60)
Loading locations...
相似试验
已完成
2 期
A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple MyelomaAdvanced Multiple MyelomaNCT01989325Pfizer77
已完成
1 期
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell TransplantationMultiple MyelomaNCT01690143University of Alabama at Birmingham45
已完成
2 期
Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple MyelomaMultiple MyelomaNCT00375791AEterna Zentaris67
已完成
2 期
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple MyelomaMultiple MyelomaNCT00135200University of Michigan Rogel Cancer Center16
进行中（未招募）
2 期
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryResectable Non-small Cell Lung CancerNCT06161441Regeneron Pharmaceuticals195